Posts

Posted on

Tekla Life Sciences Investors Declares Distribution

Tekla Life Sciences Investors Declares Distribution

BOSTON–(BUSINESS WIRE)–
On November 16, 2020, Tekla Life Sciences Investors declared a distribution of $0.40 per share. The record date for the distribution is November 27, 2020 and the payable date is December 31, 2020. The Fund will trade ex-distribution on November 25, 2020.

This distribution will automatically be paid in newly issued shares of the Fund unless otherwise instructed by the shareholder. The shares will be valued at the lower of the net asset value or market price on the pricing date, December 22, 2020. Fractional shares will generally be settled in cash, except for registered shareholders with book entry accounts at the transfer agent who will have whole and fractional shares added to their account.

Shareholders may request to be paid in cash instead of shares by responding to the bank, brokerage or nominee who holds the shares if the shares are in “street name” or by filling out an election card received from Computershare Investor Services shortly after the record date if the shares are in registered form. The bank, brokerage or nominee who holds the shares must advise the Depository Trust Company (“DTC”) as to their full and fractional share requirements by December 21, 2020. Written notification for the election of cash instead of stock by registered shareholders must be received by Computershare Investor Services prior to December 21, 2020.

Tekla Life Sciences Investors (NYSE: HQL) is a closed-end fund that invests in public and private companies in the life sciences industry. Tekla Capital Management LLC, based in Boston, serves as Investment Adviser to the Fund. Shares of the Fund can be purchased on the New York Stock Exchange through any securities broker.

For additional information, please visit www.hqcm.com or call (617) 772-8500.

Tekla Capital Management LLC

(877) 855-3434

www.teklacap.com

KEYWORDS: Massachusetts United States North America

INDUSTRY KEYWORDS: General Health Science Health Research

MEDIA:

Posted on

Tekla Healthcare Investors Declares Distribution

Tekla Healthcare Investors Declares Distribution

BOSTON–(BUSINESS WIRE)–
On November 16, 2020, Tekla Healthcare Investors declared a distribution of $0.48 per share. The record date for the distribution is November 27, 2020 and the payable date is December 31, 2020. The Fund will trade ex-distribution on November 25, 2020.

This distribution will automatically be paid in newly issued shares of the Fund unless otherwise instructed by the shareholder. The shares will be valued at the lower of the net asset value or market price on the pricing date, December 22, 2020. Fractional shares will generally be settled in cash, except for registered shareholders with book entry accounts at the transfer agent who will have whole and fractional shares added to their account.

Shareholders may request to be paid in cash instead of shares by responding to the bank, brokerage or nominee who holds the shares if the shares are in “street name” or by filling out an election card received from Computershare Investor Services shortly after the record date if the shares are in registered form. The bank, brokerage or nominee who holds the shares must advise the Depository Trust Company (“DTC”) as to their full and fractional share requirements by December 21, 2020. Written notification for the election of cash instead of stock by registered shareholders must be received by Computershare Investor Services prior to December 21, 2020.

Tekla Healthcare Investors (NYSE: HQH) is a closed-end fund that invests in public and private companies in the healthcare industry. Tekla Capital Management LLC, based in Boston, serves as Investment Adviser to the Fund. Shares of the Fund can be purchased on the New York Stock Exchange through any securities broker.

For additional information, please consult www.teklacap.com or call (877) 855-3434.

Tekla Capital Management LLC

(877) 855-3434

www.teklacap.com

KEYWORDS: Massachusetts United States North America

INDUSTRY KEYWORDS: Banking Professional Services Finance

MEDIA:

Posted on

Millicom to present at Morgan Stanley European Technology, Media & Telecom Conference

Millicom to present at Morgan Stanley European Technology, Media & Telecom Conference

Luxembourg, November 16, 2020 – Millicom International Cellular S.A. (“Millicom”) announces that Millicom’s Chief Executive Officer, Mauricio Ramos, will be presenting at the Morgan Stanley European Technology, Media & Telecom Conference, on Wednesday, November 18 at approximately 6:20 pm (Stockholm) / 5:20 pm (London) / 12:20 pm (Miami).

A live webcast and replay of the presentation will be available at the following link.

-END-

For further information, please contact

Press:


Vivian Kobeh, Corporate Communications Director
+1 786-628-5300
[email protected]

 

 

 

Investors:

Michel Morin, VP Investor Relations
1 786-628-5270
[email protected]

 

Sarah Inmon, Investor Relations Senior Manager
+1 786-628-5303
[email protected]

About Millicom

Millicom (NASDAQ U.S.: TIGO, Nasdaq Stockholm: TIGO_SDB) is a leading provider of cable and mobile services dedicated to emerging markets in Latin America and Africa. Millicom sets the pace when it comes to providing high-speed broadband and innovation around The Digital Lifestyle® services through its principal brand, TIGO. As of December 31, 2019, Millicom operating subsidiaries and joint ventures employed more than 22,000 people and provided mobile services to approximately 52 million customers, with a cable footprint of more than 11 million homes passed. Founded in 1990, Millicom International Cellular S.A. is headquartered in Luxembourg.

 

Attachment



Posted on

Morguard Real Estate Investment Trust Declares November 2020 Distribution of 4 Cents per Unit

Canada NewsWire

MISSISSAUGA, ON, Nov. 16, 2020 /CNW/ – Morguard Real Estate Investment Trust (the “Trust”) (TSX: MRT.UN) today announced that it has declared a distribution of 4 cents per unit for the month of November 2020.  The distribution will be payable on December 15, 2020 to unitholders of record as at November 30, 2020.

About Morguard Real Estate Investment Trust

The Trust is a closed-end real estate investment trust, which owns a diversified portfolio of 47 high quality retail, office and industrial income producing properties in Canada consisting of approximately 8.3 million square feet of leaseable space.

For more information, please visit Morguard.com.

SOURCE Morguard Real Estate Investment Trust

Posted on

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Zosano Pharma Corporation (ZSAN)

PR Newswire

LOS ANGELES, Nov. 16, 2020 /PRNewswire/ — Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming December 28, 2020deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Zosano Pharma Corporation (“Zosano” or the “Company”) (NASDAQ: ZSAN) securities between February 13, 2017 and September 30, 2020, inclusive (the “Class Period”).

If you suffered a loss on your Zosano investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at https://www.glancylaw.com/cases/zosano-pharma-corporation/. You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

Zosano is a clinical stage pharmaceutical company. Its lead product candidate is Qtrypta (M207), a formulation of zolmitriptan coated onto the Company’s microneedle patch. Its pivotal efficacy trial, called ZOTRIP, began in July 2016. In December 2019, Zosano submitted its New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) seeking regulatory approval for Qtrypta.

On September 30, 2020, after the market closed, Zosano disclosed receipt of a discipline review letter (“DRL”) from the FDA regarding its NDA for Qtrypta and stated that approval was not likely. According to the Company’s press release, the FDA “raised questions regarding unexpected high plasma concentrations of zolmitriptan observed in five study subjects from two pharmacokinetic studies and how the data from these subjects affect the overall clinical pharmacology section of the application.” The FDA also “raised questions regarding differences in zolmitriptan exposures observed between subjects receiving different lots of Qtrypta in the company’s clinical trials.”

On this news, the Company’s share price fell $0.92, or 57%, to close at $0.70 per share on October 1, 2020, on unusually heavy trading volume.

On October 21, 2020, Zosano disclosed receipt of a Complete Response Letter (“CRL”) from the FDA. As a result of the previously identified deficiencies, the FDA recommended that Zosano conduct a repeat bioequivalence study between three of the lots used during development.

On this news, the Company’s share price fell $0.17, or 27%, to close at $0.4440 per share on October 21, 2020, on unusually heavy trading volume.

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that the Company’s clinical results reflected differences in zolmitriptan exposures observed between subjects receiving different lots; (2) that pharmocokinetic studies submitted in connection with the Company’s NDA included patients exhibiting unexpected high plasma concentrations of zolmitriptan; (3) that, as a result of the foregoing differences among patient results, the FDA was reasonably likely to require further studies to support regulatory approval of Qtrypta; (4) that, as a result, regulatory approval of Qtrypta was reasonably likely to be delayed; and (5) as a result of the foregoing, Defendants’ public statements were materially false and misleading at all relevant times.

If you purchased or otherwise acquired the Zosano securities during the Class Period, you may move the Court no later December 28, 2020to ask the Court to appoint you as lead plaintiff. To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Charles Linehan, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to [email protected], or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.   

Follow us for updates on LinkedIn, Twitter, or Facebook.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/glancy-prongay–murray-llp-reminds-investors-of-looming-deadline-in-the-class-action-lawsuit-against-zosano-pharma-corporation-zsan-301173724.html

SOURCE Glancy Prongay & Murray LLP

Posted on

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Aurora Cannabis, Inc. (ACB)

Shareholders with losses exceeding $50,000 are encouraged to contact the firm

PR Newswire

LOS ANGELES, Nov. 16, 2020 /PRNewswire/ — Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming December 1, 2020deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Aurora Cannabis, Inc. (“Aurora” or the “Company”) (NYSE: ACB) securities between February 13, 2020 and September 4, 2020, inclusive (the “Class Period”).

If you suffered a loss on your Aurora investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at https://www.glancylaw.com/cases/aurora-cannabis-inc/. You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] or visit our website at www.glancylaw.com to learn more about your rights.

On September 8, 2020, the Company announced that it expected to record up to $1.8 billion in goodwill impairment charges in fourth quarter 2020. According to Aurora’s press release, these charges included “up to $90 million” in fixed asset impairment charges “due to production facility rationalization, and a charge of approximately $140 million in the carrying value of certain inventory, predominantly trim, in order to align inventory on hand with near term expectations for demand.”

On this news, the Company’s stock price fell $0.99 per share, or more than 11%, to close at $7.52 per share on September 8, 2020, thereby injuring investors.

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that Aurora had significantly overpaid for previous acquisitions and experienced degradation in certain assets, including its production facilities and inventory; (2) the Company’s purported “business transformation plan” and cost reset failed to mitigate the foregoing issues; (3) accordingly, it was foreseeable that the Company would record significant goodwill and asset impairment charges; and (4) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. 

Follow us for updates on LinkedIn, Twitter, or Facebook.

If you purchased or otherwise acquired Aurora securities during the Class Period, you may move the Court no later than December 1, 2020 to ask the Court to appoint you as lead plaintiff. To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Charles Linehan, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to [email protected], or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased. 

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/glancy-prongay–murray-llp-reminds-investors-of-looming-deadline-in-the-class-action-lawsuit-against-aurora-cannabis-inc-acb-301173738.html

SOURCE Glancy Prongay & Murray LLP

Posted on

NSK Monocarrier Accelerates Certification of Ventilators for COVID-19

PR Newswire

ANN ARBOR, Mich., Nov. 16, 2020 /PRNewswire/ — Responding to an urgent need for medical ventilators for health professionals in Canada, StarFish Medical – Canada’s leading medical device design and development firm – called on NSK to quickly deliver up to 7,500 Monocarrier™ linear actuator assemblies for use in their Winnipeg 2.0 Ventilator.

NSK Monocarrier Accelerates Certification of Ventilators for COVID-19

Fast Response

In early Spring 2020, the Canadian government announced Canada’s Plan to Mobilize Industry to fight COVID-19, authorizing the immediate production of ventilators by a group of companies led by StarFish Medical. Over the course of just 6 months, a redesign of the original Winnipeg Ventilator was developed, suppliers were selected, and government certification was granted.

According to Michael Stofferahn, Senior Vice President, NSK Americas, “The entire NSK Americas organization has responded with speed and precision in providing the engineering and manufacturing support that medical suppliers need in this period of crisis. That we can deliver for a company like StarFish Medical is testament to our rapid design and engineering capabilities, highly scalable production capacities, and our agile logistics platform.”

Critical Application
The Winnipeg Ventilator 2.0 employs a revolutionary “frictionless” piston design. The piston is precision-machined so that its diameter is only a fraction of a millimeter smaller than the diameter of the cylinder in which it moves along a central axis. The absence of a physical seal or contact between piston and cylinder greatly reduces the resistance to piston motion, making it possible to obtain very high flow rates.

According to StarFish Medical EVP Strategic Relationships, John Walmsley, “To drive the piston, we chose NSK’s Monocarrier for its smooth, accurate positioning and extreme durability – delivered in a small form factor – which is precisely what this new ventilator design required. NSK was our first choice for this critical function.”

StarFish presented its new ventilator design to expert review panels and received positive feedback, including from Dr. Magdy Younes, MD, the original Winnipeg Ventilator designer. Younes tested the updated version of his ventilator and called it “a masterpiece.”

Manufacturing
StarFish Medical engaged Toronto-based Celestica, Inc. a leading electronics manufacturing services company, to co-ordinate the supply chain and its vendor network for manufacturing.

“As soon as we received the StarFish innovative and manufacturable design for the new Winnipeg Ventilator 2.0, we leveraged our engineering, supply chain, and certified manufacturing expertise to source critical parts and begin production of up to 7,500 units without delay,” said Kevin Walsh, Vice President, Celestica. “These ventilators are essential to treating critically-ill COVID-19 patients, so speeding time-to-market has never been more critical. We’re proud to play a critical role in ensuring that StarFish meets its commitment to supply its ventilators to hospitals throughout Canada.” 

NSK Monocarrier™
The Monocarrier rodless linear actuator series combines three core NSK Automation technologies: precision-ground ball screws, linear guides with K1™ lubrication, and support bearings. These fully integrated components provide smooth, near-silent, high-accuracy linear positioning for up to 5 years or 10,000 km of travel without maintenance. They are available in a broad range of sizes and load capacities, from the very compact units used by StarFish Medical, to the Toughcarrier™ line of heavy-duty industrial units featuring cylindrical rollers as the rolling elements.

The Monocarrier actuator also takes advantage of NSK Automation’s mechatronics expertise, and can be easily combined with stepper or servo motors for a seamlessly integrated, preassembled and pretested component ready for installation. Multiple Monocarriers can easily be combined into an XYZ assembly or integrated with NSK linear guides and rails using readily available combination brackets, to create high-precision multi-axis robots or gantry systems. For applications ranging from semiconductor manufacturing, medical and diagnostic equipment, to 3D printers and industrial machining systems, NSK enables automation to help customers pioneer new technology, increase operational efficiency, or go to market faster.

About NSK
NSK manufactured the world’s first bearings in Japan in 1916, and has since developed into a global organization researching, designing, and manufacturing Motion & Control™ solutions essential for mobility and industrial applications. In the early 1960s, NSK set its sights outside Japan and has established over 200 business locations in 30 countries, alongside a vast network of joint ventures and partnerships in all corners of the world. Today, NSK is the top supplier of bearings in Japan and is the third largest supplier in the world by market share.

For more information, visit NSKAutomation.com

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/nsk-monocarrier-accelerates-certification-of-ventilators-for-covid-19-301172314.html

SOURCE NSK Americas

Posted on

NNOX Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Nano-X Imaging Ltd. Shareholders of Class Action and Lead Plaintiff Deadline: November 16, 2020

NNOX Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Nano-X Imaging Ltd. Shareholders of Class Action and Lead Plaintiff Deadline: November 16, 2020

NEW YORK–(BUSINESS WIRE)–
Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Nano-X Imaging Ltd. (“Nano-X” or “the Company”) (NASDAQ: NNOX) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Nano-X securities between August 21, 2020 and September 15, 2020, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/nnox.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements and/or failed to disclose that:(1) Nano-X’s commercial agreements and its customers were fabricated; (2) Nano-X’s statements regarding its “novel” Nanox System were misleading as the Company never provided data comparing its images with images from competitors’ machines; (3) Nano-X’s submission to the U.S. Food and Drug Administration (“FDA”) admitted the Nanox System was not original; and (4) as a result, defendants’ public statements were materially false and/or misleading at all relevant times.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: www.bgandg.com/nnox or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Nano-X you have until November 16, 2020 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Bronstein, Gewirtz & Grossman, LLC

Peretz Bronstein or Yael Hurwitz

212-697-6484 | [email protected]

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Legal Professional Services

MEDIA:

Logo
Logo
Posted on

ODT Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Odonate Therapeutics, Inc. Shareholders With Losses Exceeding $50K of Class Action and Lead Plaintiff Deadline: November 16, 2020

ODT Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Odonate Therapeutics, Inc. Shareholders With Losses Exceeding $50K of Class Action and Lead Plaintiff Deadline: November 16, 2020

NEW YORK–(BUSINESS WIRE)–
Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Odonate Therapeutics, Inc. (“Odonate” or the “Company”) (NASDAQ: ODT) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Odonate securities between December 7, 2017, and August 21, 2020, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/odt.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements and/or failed to disclose that:(1) tesetaxel was not as safe or well-tolerated as the Company had led investors to believe; (2) consequently, tesetaxel’s commercial viability as a cancer treatment was overstated; and (3) as a result, the Company’s public statements were materially false and misleading at all relevant times.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: www.bgandg.com/odt or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Odonate you have until November 16, 2020 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Bronstein, Gewirtz & Grossman, LLC

Peretz Bronstein or Yael Hurwitz

212-697-6484 | [email protected]

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Legal Professional Services

MEDIA:

Logo
Logo
Posted on

TransPerfect Simplifies Website Localization With Launch of GlobalLink OneLink JS

Streamlines Translation of Websites Built with JavaScript Frameworks

NEW YORK, Nov. 16, 2020 (GLOBE NEWSWIRE) — TransPerfect, the world’s largest provider of language and technology solutions for global business, today announced the launch of GlobalLink OneLink® JS, an extension of the award-winning GlobalLink OneLink website localization platform, which currently powers over 5,000 multilingual websites for leading brands across the globe.

GlobalLink
OneLink automates the process of translating and releasing websites. With nothing to install, OneLink virtually eliminates IT involvement and requires no client-side project management. Organizations can launch new multilingual websites in as few as 30 days and maintain them in sync with their source thanks to fully automated change detection. 

Built on a new JavaScript-based architecture, OneLink JS is the next generation of the OneLink product family. As an alternative to the HTTP proxy approach, OneLink JS functions without the complex engineering typically associated with localization of sites authored in JavaScript. 

With OneLink JS, users can:

  • Localize websites built with HTML or JavaScript frameworks, including React, Angular, and Vue.js
  • Reduce overall costs and turnaround times to launch digital content into multiple languages
  • Track up-to-date global usage of translated websites with JavaScript-generated tracking metrics
  • Edit translations in real time with our WYSIWYG in-context review
  • Translate content behind the firewall or in QA/testing areas without IT involvement
  • Integrate with neural AI or MT engines.

Joe Kuefler, Division President for TransPerfect’s GlobalLink OneLink group, remarked, “The proxy technology in the first version of OneLink made localizing websites simple, but now OneLink JS makes it essentially effortless. Two lines of JavaScript code and you’ve done all the technical work you need to launch a website into a new language.”

Phil Shawe, President and CEO at TransPerfect, stated, “OneLink JS is a major leap forward for website localization technology. Translating websites based on JavaScript has never been easier. I’m proud of our development teams and their relentless drive for innovation.”

For more information, visit https://globallink.translations.com/products/onelink/.

About TransPerfect

TransPerfect is the world’s largest provider of language services and technology solutions for global business. From offices in over 100 cities on six continents, TransPerfect offers a full range of services in 170+ languages to clients worldwide. More than 5,000 global organizations employ TransPerfect’s GlobalLink® Product Suite to simplify management of multilingual content. With an unparalleled commitment to quality and client service, TransPerfect is fully ISO 9001 and ISO 17100 certified. TransPerfect has global headquarters in New York, with regional headquarters in London and Hong Kong. For more information, please visit our website at www.transperfect.com.

Contact
:

Ryan
Simper
+1 212.689.5555


[email protected]